Thursday, June 11, 2026

Intelligence Β· INN directory

Pharmaceutical Drugs

Regulatory status, brand names, and pipeline context for BD, medical affairs, and competitive intelligence teams.

Drugs indexed 4,797
Companies 1,769
Pipeline programs 20,548

Quick answer

NovaPharmaNews tracks 4,797 pharmaceutical drugs by INN (International Nonproprietary Name), with US FDA approval status, brand names, originators, routes of administration, and links to pipeline programs and patents. Search by generic name or browse A–Z for competitive intelligence and medical affairs reference.

Showing page 136 of 200 Β· By data quality, then INN

  1. ruboxistaurin

    ARXXANT

    EMA: application withdrawn

  2. rucaparib

    RUBRACA

    EMA: approved

    L01XX
  3. rurioctocog alfa pegol

    ADYNOVI

    EMA: approved Β· PMDA: approved

    B02BD02
  4. sacituzumab govitecan

    TRODELVY Gilead Sciences Pty Limited

    EMA: approved Β· TGA: approved

    L01FX06
  5. samarium [153sm] lexidronam pentasodium

    QUADRAMET

    EMA: approved

    V10BX02
  6. sargramostim

    IMREPLYS

    FDA: approved Β· EMA: approved Β· PMDA: approved

    L03AA09
  7. sasanlimab

    ZUMRAD

    EMA: application withdrawn

    L01FF
  8. satavaptan

    AQUILDA

    EMA: application withdrawn

  9. satraplatin

    ORPLATNA

    EMA: application withdrawn

  10. seladelpar lysine dihydrate

    LYVDELZI (PREVIOUSLY SELADELPAR GILEAD)

    EMA: approved

    A05AX07
  11. semuloparin sodium

    MULSEVO

    EMA: application withdrawn

  12. serelaxin

    REASANZ

    EMA: refused

    C01DX21
  13. serplulimab

    HETRONIFLY

    EMA: approved Β· NMPA: clinical trials

    L01FF12
  14. sevelamer

    ARX-SEVELAMER Sanofi-aventis Healthcare Pty Ltd

    EMA: approved Β· TGA: approved

    V03AE02
  15. shingles (herpes zoster) vaccine (live)

    ZOSTAVAX

    EMA: withdrawn

    J07BK02
  16. simeprevir

    OLYSIO

    EMA: withdrawn

    J05AE14
  17. simoctocog alfa

    NUWIQ

    EMA: approved

    B02BD02
  18. sinapultide

    SURFAXIN

    EMA: application withdrawn

  19. sipavibart

    KAVIGALE

    EMA: approved Β· PMDA: approved

    J06BD09
  20. sirukumab

    PLIVENSIA

    EMA: application withdrawn

    L04AC
  21. sitagliptin fumarate

    SITAGLIPTIN SUN

    EMA: approved

    A10BH01
  22. sitagliptin hydrochloride monohydrate

    SITAGLIPTIN / METFORMIN HYDROCHLORIDE MYLAN

    EMA: approved

    A10BD07
  23. sitaxentan sodium

    THELIN

    EMA: withdrawn

    C02KX03
  24. smallpox and monkeypox vaccine (live modified vaccinia virus ankara)

    IMVANEX

    EMA: approved

    J07BX

Frequently asked questions

What is the NovaPharmaNews drugs directory?

It is a searchable index of 4,797 pharmaceutical active ingredients and their marketed profiles β€” INN, brand names, US regulatory status, manufacturers, and cross-links to clinical pipeline and patent records.

Where does drug approval data come from?

Profiles combine FDA Drugs@FDA and Orange Book references, ClinicalTrials.gov pipeline links, and editorial enrichment. See our data sources page for attribution and update cadence. This directory is for professional reference, not medical advice.

How do I find a drug by brand name?

Use the search box on this page β€” it matches both INN (generic name) and slug. Brand names appear on each drug row and on the full drug profile page, with links to the originator company when available.